Advertisement
Document › Details
Alligator Bioscience AB. (3/5/20). "Press Release: Alligator Bioscience Appoints Andreas Johannesson as Interim Chief Financial Officer". Lund.
Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that Andreas Johannesson has been appointed interim CFO, effective 5 March 2020. The recruitment process for a permanent CFO is ongoing. As previously announced, Per-Olof Schrewelius will leave the position as CFO at Alligator.
Andreas brings to Alligator a wealth of experience from various CFO, interim CFO and other financial positions in international companies like Metso, Haldex, Åhléns, Fitness24Seven and orthopedic business TeamOlmed. Andreas also has a background in strategic consultancy within R&D and Innovation through appointments at McKinsey and Connecta.
For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com.
The information was submitted for publication, through the agency of the contact person set out above, at 1:45 p.m. CET on 5 March 2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes six lead clinical and preclinical drug candidates: mitazalimab (ADC-1013), ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.), ATOR-1144 and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit http://www.alligatorbioscience.com.
Record changed: 2023-06-05 |
Advertisement
More documents for Alligator Bioscience (Group)
- [1] Alligator Bioscience AB. (3/22/23). "Press Release: Alligator Intends to Carry Out a 91 Percent Secured Rights Issue of Units of Approximately SEK 199 Million [Not for US, AU, et al.]"....
- [2] Alligator Bioscience AB. (4/15/21). "Press Release: Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy". Lund....
- [3] Alligator Bioscience AB. (3/18/21). "Press Release: Alligator Bioscience Appoints Søren Bregenholt as New CEO". Lund....
- [4] Alligator Bioscience AB. (2/12/20). "Press Release: Alligator Bioscience AB Year-end Report January-December 2019"....
- [5] Alligator Bioscience AB. (12/17/19). "Press Release: First Patient Dosed with ATOR-1017 Developed for Metastasized Cancer". Lund....
- [6] Alligator Bioscience AB. (12/11/19). "Press Release: CFO Per-Olof Schrewelius Leaves Alligator Bioscience". Lund....
- [7] Alligator Bioscience AB. (11/29/19). "Press Release: Alligator Bioscience AB Appoints Chief Operating Officer". Lund....
- [8] Alligator Bioscience AB. (8/20/19). "Press Release: Alligator Bioscience Signs Antibody Agreement for Greater China with Biotheus Inc.". Lund....
- [9] Alligator Bioscience AB. (7/31/19). "Press Release: Alligator Bioscience Regains Global Rights from Janssen to CD40 Agonistic Antibody, ADC-1013 (JNJ-64457107)". Lund....
- [10] Alligator Bioscience AB. (1/7/19). "Press Release: Alligator Bioscience Launches RUBY, a Novel Concept in Bispecific Antibody Formats". Lund....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top